This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Another Great Depression Imminent or Is it Just a Myth?
by Urmimala Biswas
Asian countries have already shown clear signs of major economic recession.
Thermo Fisher Expands Lab Plastic Making for Coronavirus Support
by Zacks Equity Research
Thermo Fisher (TMO) consumables already support critical COVID-19 work and include sample collection vials and lab essentials.
LabCorp (LH) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, LabCorp (LH) closed at $183.13, marking a +0.91% move from the previous day.
LabCorp (LH) Stock Moves -1.24%: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $174.72 in the latest trading session, marking a -1.24% move from the prior day.
LabCorp (LH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
LabCorp (LH) closed at $177.41 in the latest trading session, marking a +1.81% move from the prior day.
Why Is LabCorp (LH) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
LabCorp (LH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp (LH) Banks on Covance Amid Testing Volume Pressure
by Zacks Equity Research
LabCorp's (LH) COVID-19 related research too has been progressing well.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.
Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.
Boston Scientific (BSX) Q2 Earnings Top, Margins Decline
by Zacks Equity Research
This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.
Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.
Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.
LabCorp (LH) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
LabCorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LabCorp (LH) Beats Q2 Earnings Estimates, Margins Decline
by Zacks Equity Research
LabCorp (LH) witnesses a 20.7% decline in organic volume, partially offset by acquisition volume growth of 1.2%.
Is Laboratory Corporation of America Holdings (LH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (LH) Outperforming Other Medical Stocks This Year?
LabCorp (LH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
LabCorp (LH) delivered earnings and revenue surprises of 229.49% and 14.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?
by Zacks Equity Research
Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.
Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.
Why Earnings Season Could Be Great for LabCorp (LH)
by Zacks Equity Research
LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.